Akebia Therapeutics’ drug, Vafseo, has received FDA approval for treating anemia in adults with chronic kidney disease. The drug, vadadustat, is an oral medication that mimics the effects of high altitude to stimulate the production of erythropoietin, a hormone that regulates red blood cell production. Despite safety concerns, including a black box warning for cardiovascular risks, Vafseo offers a more convenient treatment option compared to existing injectable therapies. The approval of Vafseo is part of recent regulatory news that includes approvals for drugs addressing pulmonary arterial hypertension, neuromyelitis optica spectrum disorder, fatty liver disease, Duchenne muscular dystrophy, metachromatic leukodystrophy, and various types of cancers.
Source link
Akebia Recovers From Rejection to Win FDA Approval for Anemia Drug
